Sunitinib paves the way for targeted therapies in neuroendocrine tumors.
- Published in:
- 2009
- By:
- Publication type:
- journal article
Works matching IS 17762596 AND DT 2009 AND VI 4 AND IP 4
Results: 8
1
2
Implications of KRAS mutation status for the treatment of metastatic colorectal cancer.
- Published in:
- 2009
- By:
- Publication type:
- journal article
3
Targeting mitogen-activated protein kinase kinase (MEK) in solid tumors.
- Published in:
- 2009
- By:
- Publication type:
- journal article
4
Sorafenib-induced hand-foot skin reaction: a Koebner phenomenon?
- Published in:
- 2009
- By:
- Publication type:
- journal article
5
Axitinib--a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor.
- Published in:
- 2009
- By:
- Publication type:
- journal article
6
Targeting insulin-like growth factor type 1 receptor in cancer therapy.
- Published in:
- 2009
- By:
- Publication type:
- journal article
7
Molecular targeted therapies in the treatment of gastroenteropancreatic neuroendocrine tumors.
- Published in:
- 2009
- By:
- Publication type:
- journal article
8
Targeted therapies in thyroid cancer.
- Published in:
- 2009
- By:
- Publication type:
- journal article